Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Simon P. Graham; Rebecca K. McLean; Alexandra J. Spencer; Sandra Belij-Rammerstorfer; Daniel Wright; Marta Ulaszewska; Jane C. Edwards; Jack W.P. Hayes; Veronica Martini; Nazia Thakur; Carina Conceicao; Isabelle Dietrich; Holly Shelton; Ryan Waters; Anna Ludi; Ginette Wilsden; Clare Browning; Dagmara Bialy; Sushant Bhat; Phoebe Stevenson-Leggett; Philippa Hollinghurst; Ciaran Gilbride; David Pulido; Katy Moffat; Hannah Sharpe; Elizabeth Allen; Valerie Mioulet; Chris Chiu; Joseph Newman; Amin S. Asfor; Alison Burman; Sylvia Crossley; Jiandong Huo; Raymond J. Owens; Miles Carroll; John A. Hammond; Elma Tchilian; Dalan Bailey; Bryan Charleston; Sarah C. Gilbert; Tobias J. Tuthill; Teresa Lambe

doi:10.1038/s41541-020-00221-3

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Simon P. Graham^*, Rebecca K. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, Jane C. Edwards, Jack W.P. Hayes, Veronica Martini, Nazia Thakur, Carina Conceicao, Isabelle Dietrich, Holly Shelton, Ryan Waters, Anna Ludi, Ginette Wilsden, Clare Browning, Dagmara Bialy, Sushant Bhat, Phoebe Stevenson-LeggettPhilippa Hollinghurst, Ciaran Gilbride, David Pulido, Katy Moffat, Hannah Sharpe, Elizabeth Allen, Valerie Mioulet, Chris Chiu, Joseph Newman, Amin S. Asfor, Alison Burman, Sylvia Crossley, Jiandong Huo, Raymond J. Owens, Miles Carroll, John A. Hammond, Elma Tchilian, Dalan Bailey, Bryan Charleston, Sarah C. Gilbert, Tobias J. Tuthill, Teresa Lambe

^*Corresponding author for this work

Research & Development Institute Divisional Office

Research output: Contribution to journal › Article › peer-review

107 Citations (Scopus)

18 Downloads (Pure)

Abstract

Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.

Original language	English
Article number	69
Journal	npj Vaccines
Volume	5
Issue number	1
Early online date	27 Jul 2020
DOIs	https://doi.org/10.1038/s41541-020-00221-3
Publication status	Published - 1 Dec 2020

Bibliographical note

Funding Information: This study was supported by UKRI Engineering and Physical Sciences Research Council (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme and Core Capability Grants to The Pirbright Institute (BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/ 00007037 and BBS/E/I/00007039), and the Bill and Melinda Gates Foundation supported ‘Pirbright Livestock Antibody Hub’ (Grant No. OPP1215550). Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C and EPSRC Grant No. EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Snaith for animal husbandry and the Jenner Institute Vector Core Facility for assistance, and The Pirbright Institute Animal Services Team for animal care and provision of samples.

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Publisher Copyright: © The Author(s) 2020

Citation: Graham, S.P., McLean, R.K., Spencer, A.J. et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines 5, 69 (2020).

DOI: https://doi.org/10.1038/s41541-020-00221-3

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41541-020-00221-3Licence: CC BY

Graham2020EvaluationOfTheImmunogenicityOfPrime-boostVaccinationWithTheReplication-deficientViralnpjVaccinesFinal published version, 1.11 MBLicence: CC BY

Cite this

Graham, S. P., McLean, R. K., Spencer, A. J., Belij-Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J. C., Hayes, J. W. P., Martini, V., Thakur, N., Conceicao, C., Dietrich, I., Shelton, H., Waters, R., Ludi, A., Wilsden, G., Browning, C., Bialy, D., Bhat, S., ... Lambe, T. (2020). Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines, 5(1), Article 69. https://doi.org/10.1038/s41541-020-00221-3

@article{592b886932774668b995c3d2fc1cd706,

title = "Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19",

abstract = "Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.",

author = "Graham, \{Simon P.\} and McLean, \{Rebecca K.\} and Spencer, \{Alexandra J.\} and Sandra Belij-Rammerstorfer and Daniel Wright and Marta Ulaszewska and Edwards, \{Jane C.\} and Hayes, \{Jack W.P.\} and Veronica Martini and Nazia Thakur and Carina Conceicao and Isabelle Dietrich and Holly Shelton and Ryan Waters and Anna Ludi and Ginette Wilsden and Clare Browning and Dagmara Bialy and Sushant Bhat and Phoebe Stevenson-Leggett and Philippa Hollinghurst and Ciaran Gilbride and David Pulido and Katy Moffat and Hannah Sharpe and Elizabeth Allen and Valerie Mioulet and Chris Chiu and Joseph Newman and Asfor, \{Amin S.\} and Alison Burman and Sylvia Crossley and Jiandong Huo and Owens, \{Raymond J.\} and Miles Carroll and Hammond, \{John A.\} and Elma Tchilian and Dalan Bailey and Bryan Charleston and Gilbert, \{Sarah C.\} and Tuthill, \{Tobias J.\} and Teresa Lambe",

note = "Funding Information: This study was supported by UKRI Engineering and Physical Sciences Research Council (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme and Core Capability Grants to The Pirbright Institute (BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/ 00007037 and BBS/E/I/00007039), and the Bill and Melinda Gates Foundation supported {\textquoteleft}Pirbright Livestock Antibody Hub{\textquoteright} (Grant No. OPP1215550). Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C and EPSRC Grant No. EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by the UK Department for Environment Food \& Rural Affairs. We thank V. Clark, H. Gray, and R. Snaith for animal husbandry and the Jenner Institute Vector Core Facility for assistance, and The Pirbright Institute Animal Services Team for animal care and provision of samples. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article{\textquoteright}s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article{\textquoteright}s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Publisher Copyright: {\textcopyright} The Author(s) 2020 Citation: Graham, S.P., McLean, R.K., Spencer, A.J. et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines 5, 69 (2020). DOI: https://doi.org/10.1038/s41541-020-00221-3",

year = "2020",

month = dec,

day = "1",

doi = "10.1038/s41541-020-00221-3",

language = "English",

volume = "5",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Research",

number = "1",

}

Graham, SP, McLean, RK, Spencer, AJ, Belij-Rammerstorfer, S, Wright, D, Ulaszewska, M, Edwards, JC, Hayes, JWP, Martini, V, Thakur, N, Conceicao, C, Dietrich, I, Shelton, H, Waters, R, Ludi, A, Wilsden, G, Browning, C, Bialy, D, Bhat, S, Stevenson-Leggett, P, Hollinghurst, P, Gilbride, C, Pulido, D, Moffat, K, Sharpe, H, Allen, E, Mioulet, V, Chiu, C, Newman, J, Asfor, AS, Burman, A, Crossley, S, Huo, J, Owens, RJ, Carroll, M, Hammond, JA, Tchilian, E, Bailey, D, Charleston, B, Gilbert, SC, Tuthill, TJ & Lambe, T 2020, 'Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19', npj Vaccines, vol. 5, no. 1, 69. https://doi.org/10.1038/s41541-020-00221-3

TY - JOUR

T1 - Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

AU - Graham, Simon P.

AU - McLean, Rebecca K.

AU - Spencer, Alexandra J.

AU - Belij-Rammerstorfer, Sandra

AU - Wright, Daniel

AU - Ulaszewska, Marta

AU - Edwards, Jane C.

AU - Hayes, Jack W.P.

AU - Martini, Veronica

AU - Thakur, Nazia

AU - Conceicao, Carina

AU - Dietrich, Isabelle

AU - Shelton, Holly

AU - Waters, Ryan

AU - Ludi, Anna

AU - Wilsden, Ginette

AU - Browning, Clare

AU - Bialy, Dagmara

AU - Bhat, Sushant

AU - Stevenson-Leggett, Phoebe

AU - Hollinghurst, Philippa

AU - Gilbride, Ciaran

AU - Pulido, David

AU - Moffat, Katy

AU - Sharpe, Hannah

AU - Allen, Elizabeth

AU - Mioulet, Valerie

AU - Chiu, Chris

AU - Newman, Joseph

AU - Asfor, Amin S.

AU - Burman, Alison

AU - Crossley, Sylvia

AU - Huo, Jiandong

AU - Owens, Raymond J.

AU - Carroll, Miles

AU - Hammond, John A.

AU - Tchilian, Elma

AU - Bailey, Dalan

AU - Charleston, Bryan

AU - Gilbert, Sarah C.

AU - Tuthill, Tobias J.

AU - Lambe, Teresa

N1 - Funding Information: This study was supported by UKRI Engineering and Physical Sciences Research Council (EPSRC) award EP/R013756/1 (VaxHub), UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme and Core Capability Grants to The Pirbright Institute (BBS/E/I/00007031, BBS/E/I/00007034, BBS/E/I/ 00007037 and BBS/E/I/00007039), and the Bill and Melinda Gates Foundation supported ‘Pirbright Livestock Antibody Hub’ (Grant No. OPP1215550). Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C and EPSRC Grant No. EP/S025243/1 to the Rosalind Franklin Institute. A.L., G.W., C.B., A.B., and V.M. are supported by the UK Department for Environment Food & Rural Affairs. We thank V. Clark, H. Gray, and R. Snaith for animal husbandry and the Jenner Institute Vector Core Facility for assistance, and The Pirbright Institute Animal Services Team for animal care and provision of samples. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Publisher Copyright: © The Author(s) 2020 Citation: Graham, S.P., McLean, R.K., Spencer, A.J. et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. npj Vaccines 5, 69 (2020). DOI: https://doi.org/10.1038/s41541-020-00221-3

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.

AB - Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.

UR - http://www.scopus.com/inward/record.url?scp=85088558885&partnerID=8YFLogxK

U2 - 10.1038/s41541-020-00221-3

DO - 10.1038/s41541-020-00221-3

M3 - Article

AN - SCOPUS:85088558885

SN - 2059-0105

VL - 5

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 69

ER -

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this